Zeneca in fine health
Article Abstract:
Zeneca has reported a rise in underlying profit of 22% which is above target for the long term, though margins could be reduced by new product launches. Analysts tend to favor Zeneca stocks, emphasising the company's growth potential. Brokers rating the company's stocks a buy include Salomon Brothers, BZW, Greig Middleton and Panmure Gordon. Societe Generale Strauss Turnbull rates the stocks a hold. Morgan Stanley has revised upwards a forecast for Zeneca's profit, though does not hold out for much of a rise in the company's stock price.
Publication Name: Investors Chronicle
Subject: Business
ISSN: 0261-3115
Year: 1997
User Contributions:
Comment about this article or add new information about this topic:
Smithkline fit and well
Article Abstract:
SmithKline Beecham shares performed well in 1995. The company's shares have been assessed by six stockbrokers, with a division of opinion between holders and buyers. Buyers include Merrill Lynch which sees cost pressures improving, demand recovering and benefits from new products due to be launched. Holders include SGST, though this broker sees an improvement in the share price from 1998 as the impact of new drugs is felt on the company's results.
Publication Name: Investors Chronicle
Subject: Business
ISSN: 0261-3115
Year: 1996
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Interesting times ahead. Equities and the credit risk premium. Hot property - or not?
- Abstracts: The real interest rate puzzle. The real interest rates puzzle
- Abstracts: SmithKline riding high. Glaxo has four fans. Oxford GlycoSciences
- Abstracts: Good sports. Game for sports management. Sport Entertainment and Media Group
- Abstracts: Harvey Nichols: store of value. Beale. Target Corporation